We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.98%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$3.11B
AUM Growth
+$217M
Cap. Flow
-$278M
Cap. Flow %
-8.93%
Top 10 Hldgs %
51.56%
Holding
91
New
16
Increased
7
Reduced
4
Closed
14

Top Buys

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$76.3M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$56M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$42.7M
4
CYTK icon
Cytokinetics
CYTK
+$38.4M
5
ALGS icon
Aligos Therapeutics
ALGS
+$29.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$383M
2
ALLK
Allakos
ALLK
+$55M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.8M
4
CGEN icon
Compugen
CGEN
+$38.7M
5
QURE icon
uniQure
QURE
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$388M 12.47%
1,765,560
– –
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$288M 9.25%
1,114,188
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$151M 4.84%
2,075,905
– –
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$147M 4.72%
4,345,016
– –
PMVP icon
5
PMV Pharmaceuticals
PMVP
$59.2M
$140M 4.48%
2,268,236
– –
RVMD icon
6
Revolution Medicines
RVMD
$39.9B
$131M 4.21%
3,309,264
– –
ODT
7
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$108M 3.46%
5,607,086
+400,000
+8% +$6.17M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$94.6M 3.04%
1,094,000
– –
RCKT icon
9
Rocket Pharmaceuticals
RCKT
$340M
$80.4M 2.58%
1,466,051
– –
SPRY icon
10
ARS Pharmaceuticals
SPRY
$509M
$77.6M 2.5%
+1,675,377
New +$56M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$70.1M 2.25%
400,000
– –
BDTX icon
12
Black Diamond Therapeutics
BDTX
$96.8M
$64.6M 2.08%
2,014,858
– –
LABD icon
13
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$56.9M 1.83%
225,000
+200,000
+800% +$76.3M
RCUS icon
14
Arcus Biosciences
RCUS
$3.55B
$54.1M 1.74%
2,084,883
– –
RLAY icon
15
Relay Therapeutics
RLAY
$4.1B
$53.8M 1.73%
1,294,132
+42,173
+3% +$1.91M
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$53.7M 1.73%
2,325,000
– –
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.69B
$50.9M 1.64%
2,287,782
– –
ARGX icon
18
argenx
ARGX
$53.4B
$50.3M 1.62%
170,926
– –
PASG icon
19
Passage Bio
PASG
$14.4M
$49.3M 1.58%
96,416
– –
CYTK icon
20
Cytokinetics
CYTK
$10.5B
$43.6M 1.4%
+2,100,000
New +$38.4M
KNTE
21
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$42.4M 1.36%
+1,064,665
New +$42.7M
ALGS icon
22
Aligos Therapeutics
ALGS
$26.2M
$42.2M 1.36%
+61,042
New +$29.7M
NRIX icon
23
Nurix Therapeutics
NRIX
$2.41B
$40.3M 1.29%
1,224,892
-129,500
-10% -$4.29M
BCEL
24
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$35.6M 1.14%
2,202,333
– –
KURA icon
25
Kura Oncology
KURA
$800M
$34.3M 1.1%
1,050,289
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Boxer Capital held 91 positions worth $3.11B, up 7.5% from $2.89B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital withdrew a net $278M in Q4 2020, closing 14 positions and reducing 4 holdings. Its most notable exit was Immunomedics Inc, an estimated $383M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Boxer Capital opened a new position in ARS Pharmaceuticals worth $77.6M.

  • Boxer Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 1,675,377 shares worth $77.6M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q4 2020, an estimated $76.3M increase.
  • Boxer Capital's biggest Q4 2020 reduction was uniQure, cutting an estimated $21.7M.
  • Boxer Capital fully exited Immunomedics Inc in Q4 2020, selling an estimated $383M.
  • Boxer Capital's ten largest holdings make up 52% of its $3.11B portfolio in Q4 2020.
  • Boxer Capital opened 16 new positions and closed 14 in Q4 2020.
  • Boxer Capital's portfolio value rose 7.5% quarter-over-quarter to $3.11B.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.